Crossmark

Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study

Crossref DOI link: https://doi.org/10.1038/s41392-024-01941-x

Published Online: 2024-09-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zeng, Zhiyong

Yang, Apeng

Yang, Jingke

Zhang, Sheng

Xing, Zhen

Wang, Xingfu

Mei, Wenzhong

Jiang, Changzhen

Lin, Junfang

Wu, Xiyue

Xue, Yihui

Wu, Zanyi

Yu, Lianghong

Wang, Dengliang

Chen, Jianwu

Zheng, Shufa

Lin, Qiaoxian

Chen, Qingjiao

Dong, Jinfeng

Zheng, Xiaoqiang

Wang, Jizhen

Huang, Jinlong

Chen, Zhenying

Chen, Ping

Zheng, Meihong

Zhou, Xiaofang

He, Youwen https://orcid.org/0000-0002-8983-2684
Lin, Yuanxiang

Chen, Junmin
License Information

Text and Data Mining valid from 2024-09-04

Version of Record valid from 2024-09-04
More Information

Article History

Received: 9 April 2024

Revised: 17 July 2024

Accepted: 28 July 2024

First Online: 4 September 2024

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below